Thanks for the thorough summary of all the issues with SBFM! On a good note, their subsid NoraPharma generated quarterly revenue of $5.5M and are expected to continue quarterly growth. Annually that would be about $22M which if memory serves me correctly NoraPharma was at $15M/year when purchased by SBFM.
Needless to say SBFM has a lot of hurdles to overcome so we'll see what happens in the coming days/weeks/months/years.
PS: Aegis thinks they are worth $2.60/share so we'll see about that too!